News & Events
Elastagen and Endoluminal Sciences secure $4.5m funding from NSW Health Medical Devices Fund
01 / 08 / 2013
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR reverse PAH
30 / 07 / 2013
KaloBios Provides Update on Pipeline of Clinical Programs
28 / 06 / 2013
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of its ongoing clinical programs for KB003, KB001-A and KB004, its pipeline of proprietary monoclonal antibodies in development for severe respiratory diseases and cancer.
Sunshine Heart Awarded 2013 Australian International Design Award for Flagship C-Pulse(R) Device
17 / 06 / 2013
Sunshine Heart Announces Corporate Updates and First Quarter 2013 Financial Results
14 / 05 / 2013
EDEN PRAIRIE, Minn., May 14, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced corporate updates and financial results for the first quarter ended March 31, 2013.
Sunshine Heart, Inc. Announces First Patient Implanted in C-Pulse System European Post-Market Study
09 / 05 / 2013
World-First Study Predicts Epilepsy Seizures in Humans
07 / 05 / 2013
A small device implanted in the brain has accurately predicted epilepsy seizures in humans in a world-first study led by Professor Mark Cook, Chair of Medicine at the University of Melbourne and Director of Neurology at St Vincent's Hospital.
Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award
07 / 05 / 2013
Neuromonics Unveils New Device to Relieve Mild, Moderate Tinnitus at Audiology NOW!
28 / 03 / 2013
â?? Neuromonics Sanctuaryâ?¢ provides on-demand tinnitus relief â??
APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATOR� Technology
22 / 03 / 2013
Applied Physiology® Pty Ltd today announced that the U.S. Patent and Trademark Office has awarded a key patent for its unique Navigator� technology for clinical decision support of circulatory management.
NEUROVANCE RECEIVES NOTICE OF ALLOWANCE FOR COMPOSITION OF MATTER PATENT AND INITIATES CLINICAL TRIAL
19 / 02 / 2013
Cambridge, MA â?? February 19, 2013 â?? Neurovance, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a composition of matter patent for EB-1020. The patent provides Neurovance with proprietary protection for EB-1020 through July 2026.
KaloBios Pharmaceuticals Completes Initial Public Offering
08 / 02 / 2013
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share.
Sunshine Heart Appoints Warren Watson to Board of Directors
30 / 01 / 2013
Seasoned Leader in Cardiology Joins as Director Replacing William Peters